Veru (NASDAQ:VERU) Stock Rating Lowered by Wall Street Zen

Veru (NASDAQ:VERU) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

VERU has been the subject of a number of other research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 target price on shares of Veru in a report on Thursday, June 4th. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Finally, Oppenheimer reduced their target price on shares of Veru from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $24.50.

Veru Price Performance

NASDAQ VERU opened at $2.73 on Friday. The stock has a market capitalization of $46.55 million, a P/E ratio of -3.07 and a beta of -1.15. Veru has a 52-week low of $2.05 and a 52-week high of $7.33. The firm has a 50-day moving average price of $2.70 and a 200 day moving average price of $2.50.

Veru (NASDAQ:VERU) last released its earnings results on Monday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, equities research analysts expect that Veru will post -1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new stake in shares of Veru during the 4th quarter valued at $2,140,000. Marshall Wace LLP acquired a new position in shares of Veru in the 2nd quarter valued at approximately $220,000. Qube Research & Technologies Ltd bought a new stake in shares of Veru during the second quarter worth $152,000. Sender Co & Partners Inc. increased its holdings in Veru by 82.8% during the 2nd quarter. Sender Co & Partners Inc. now owns 238,231 shares of the company’s stock worth $139,000 after purchasing an additional 107,911 shares in the last quarter. Finally, FNY Investment Advisers LLC bought a new position in shares of Veru during the second quarter worth about $328,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.